Filgotinib effective as maintenance treatment for ulcerative colitis

The phase 2b/3 SELECTION study found that the JAK1 inhibitor filgotinib was effective and well tolerated as maintenance treatment for patients with moderately- to severely-active ulcerative colitis who had achieved clinical response to induction treatment with this drug [1]. Filgotinib is being investigated for several inflammatory conditions, including ulcerative colitis. The SELECTION maintenance study evaluated maintenance treatment with filgotinib in 664 patients with moderately- to severely-active ulcerative colitis who achieved clinical remission or Mayo Clinic Score (MCS) response after 10 weeks of induction with filgotinib 100 mg or 200 mg or placebo. Approximately 40% of patients were biologic-experienced. Patients randomised to filgotinib induction were re-randomised to their induction filgotinib dose or placebo. Patients randomised to placebo...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 2 November, 20202 November, 2020